GSK PLC (GSK)
39.60
-0.35
(-0.88%)
USD |
NYSE |
Apr 17, 16:00
39.55
-0.05
(-0.13%)
Pre-Market: 08:15
GSK Cash from Operations (Quarterly): 3.899B for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.899B |
| September 30, 2023 | 2.821B |
| June 30, 2023 | 1.638B |
| March 31, 2023 | 64.42M |
| December 31, 2022 | 2.697B |
| September 30, 2022 | 1.220B |
| June 30, 2022 | 1.841B |
| March 31, 2022 | 3.411B |
| December 31, 2021 | 5.170B |
| September 30, 2021 | 3.502B |
| June 30, 2021 | 1.812B |
| March 31, 2021 | 456.28M |
| December 31, 2020 | 4.907B |
| September 30, 2020 | 1.307B |
| June 30, 2020 | 3.383B |
| March 31, 2020 | 1.237B |
| December 31, 2019 | 4.613B |
| September 30, 2019 | 2.990B |
| June 30, 2019 | 1.773B |
| March 31, 2019 | 863.72M |
| December 31, 2018 | 5.632B |
| September 30, 2018 | 2.572B |
| June 30, 2018 | 1.832B |
| March 31, 2018 | 1.200B |
| December 31, 2017 | 3.632B |
| Date | Value |
|---|---|
| September 30, 2017 | 2.549B |
| June 30, 2017 | 1.334B |
| March 31, 2017 | 1.417B |
| December 31, 2016 | 4.198B |
| September 30, 2016 | 2.107B |
| June 30, 2016 | 1.778B |
| March 31, 2016 | 720.05M |
| December 31, 2015 | 2.271B |
| September 30, 2015 | 755.80M |
| June 30, 2015 | 338.30M |
| March 31, 2015 | 560.83M |
| December 31, 2014 | 3.580B |
| September 30, 2014 | 2.103B |
| June 30, 2014 | 1.315B |
| March 31, 2014 | 1.534B |
| December 31, 2013 | 3.492B |
| September 30, 2013 | 3.264B |
| June 30, 2013 | 2.606B |
| March 31, 2013 | 1.937B |
| December 31, 2012 | 3.047B |
| September 30, 2012 | -465.79M |
| June 30, 2012 | 2.762B |
| March 31, 2012 | 1.590B |
| December 31, 2011 | 3.414B |
| September 30, 2011 | 2.895B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
64.42M
Minimum
Mar 2023
5.170B
Maximum
Dec 2021
2.565B
Average
2.697B
Median
Dec 2022
Cash from Operations (Quarterly) Benchmarks
| AstraZeneca PLC | 2.38B |
| Haleon PLC | -- |
| Novo Nordisk A/S | 1.302B |
| Pfizer Inc | 5.24B |
| Sanofi SA | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 374.35M |
| Cash from Financing (Quarterly) | -4.425B |
| Free Cash Flow | 5.505B |
| Free Cash Flow Per Share (Quarterly) | 1.436 |
| Free Cash Flow to Equity (Quarterly) | 6.965B |
| Free Cash Flow to Firm (Quarterly) | 3.286B |
| Free Cash Flow Yield | 6.38% |